4 Healthcare Stock Stories To Enhance Investment Wellness

GlaxoSmithKline (NYSE:GSK): Closing price $50.37

Employees of the United Kingdom pharmaceuticals major have been detained by police in Beijing, Shanghai and Changsha, subsequent to claims of data fraud and bribery in Glaxo’s mainland operations. Last week, police seized a number of persons at the company’s Shanghai office, among which included a senior foreign finance executive. A source in Shanghai’s pharmaceutical sector said that they also took employees from the company’s Beijing office into custody.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GSK

Zoetis (NYSE: ZTS): Current price $29.72

At one time the animal health business division of Pfizer (NYSE:PFE), Zoetis announced plans to expand its manufacturing facility in Lincoln, Nebraska, to make easier the output of high-quality, reliable medicines for veterinarians, livestock producers and the animals under their care. The company anticipates that this expansion should affirm its longstanding commitment to being a world-class manufacturer of animal health products, and also to continue to be an employer of choice in Lincoln. The plan requires a 19,000-square-foot, three-story expansion of the existing production installation to accommodate the transfer of products from a third-party manufacturer to the capital. Zoetis expects to finalize construction next year.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ZTS

Baxter International (NYSE:BAX): Closing price $69.66

On Tuesday, Baxter presented two comprehensive analyses in support of the proven clinical and real-world results of ADVATE (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free Method) during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis in Amsterdam. The presentations feature two complementary evaluations of the ADVATE profile, including an analysis of post-marketing data from about 1,200 hemophilia A patients from 15 countries, together with safety findings from a 10-year database of 12 clinical trials.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BAX

ARIAD Pharmaceuticals (NASDAQ:ARIA): Closing price $19.41

ARIAD announced Tuesday that the European Commission has granted a marketing authorization for Iclusig (ponatinib) as an orphan medicinal product for two indications: the treatment of adult patients suffering from chronic phase, accelerated phase or blast phase chronic myeloid leukaemia, who are resistant to dasatinib or nilotinib; the treatment of patients who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; those who have the T315I mutation, and, the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukaemia, who are resistant to dasatinib; those who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or patients who have the T315I mutation.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ARIA

Investing Insights: Will An Acquisition Boost Pfizer?